INLB (Item 9 Labs) Beta: -0.9781 (As of Jun. 25, 2026)


INLB Item 9 Labs Corp INLB
12 GF Score
Price $0.00
View Full Analysis

What is Item 9 Labs Beta?

Item 9 Labs INLB -99.00% 12 Beta is -0.9781 as of Jun. 25, 2026. GuruFocus rates INLB with a GF Score™ of 12/100.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-25), Item 9 Labs's Beta is -0.9781.


Item 9 Labs  (OTCPK:INLB) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Item 9 Labs Beta Related Terms


Item 9 Labs Beta Historical Data

* Premium members only.

The historical data trend for Item 9 Labs's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Item 9 Labs Beta Chart

Item 9 Labs Annual Data
Trend Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.48 1.74 0.49 0.17 0.99

Item 9 Labs Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.00 0.99 1.25 1.49 1.56

INLB vs NEPT, CENBF, SGBI: Beta Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Item 9 Labs's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Item 9 Labs Beta vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Item 9 Labs's Beta distribution charts can be found below:

* The bar in red indicates where Item 9 Labs's Beta falls into.


INLB
12GF Score
Item 9 Labs Corp INLB
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Item 9 Labs Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of -0.9781 mean?
Item 9 Labs (INLB) has a Beta of -0.9781 as of Jun. 25, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Item 9 Labs and its competitors.
Is Item 9 Labs' Beta too high?
Item 9 Labs' current Beta is -0.9781. Overall, Item 9 Labs has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Item 9 Labs' Beta compare to NEPT and CENBF?
Item 9 Labs' Beta of -0.9781 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Drug Manufacturers company?
A good Beta depends on the Drug Manufacturers industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Item 9 Labs and its competitors. Item 9 Labs's current Beta is -0.9781. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Item 9 Labs stock overvalued right now?
Item 9 Labs (INLB) has a current Beta of -0.9781. The current Beta is -0.9781. Item 9 Labs' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Item 9 Labs (INLB), the current Beta is -0.9781 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Item 9 Labs Business Description

Address 2111 E. Highland Avenue, Suite B375, Phoenix, AZ, USA, 85016
Item 9 Labs Corp is a vertically integrated cannabis operator and dispensary franchisor delivering premium products from its large-scale cultivation and production facilities in the United States. The Item 9 Labs brand specializes in products and user experience across several cannabis categories. The company also offers a dispensary franchise model through the national Unity Rd. retail brand. Easing barriers to entry, the franchise provides an opportunity for both new and existing dispensary owners to leverage the knowledge, resources, and ongoing support needed to thrive in their state compliantly and successfully. It also brings industry practices to markets nationwide through distinctive retail experience, cultivation capabilities, and product innovation.
12GF Score

Get the complete analysis for INLB

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price